Alector, Inc., a clinical stage biopharmaceutical company headquartered in South San Francisco, California, is making strides in developing therapies for the treatment of neurodegeneration diseases. One of its primary products, AL001, is currently in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases. AL101, another key product, is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company is also developing AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease, and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Alector's pipeline products include AL044, which targets MS4A4A, a risk gene for Alzheimer's disease. To further its research and development efforts, Alector has a collaboration agreement with Adimab, LLC for antibodies, as well as a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies to treat neurodegenerative diseases, such as AL001, AL002, and AL101. Founded in 2013, Alector, Inc. is a company to watch in the field of neurodegenerative disease treatment.
Alector's ticker is ALEC
The company's shares trade on the NASDAQ stock exchange
They are based in South San Francisco, California
There are 51-200 employees working at Alector
It is alector.com/about-us
Alector is in the Healthcare sector
Alector is in the Biotechnology industry
The following five companies are Alector's industry peers: